Physician profile
Concey Ramold
NPI 1427459551
$1,578.79
in general payments reported to CMS, 2019-2025
13 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.53 · 2022: $93.89 · 2023: $750 · 2024: $200 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.46 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $594.58 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $199.93 | 2023-2025 | Spravato, Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $198.21 | 2022-2025 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $189.02 | 2022-2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $85.95 | 2025 | Jornay Pm |
| Abbvie INC. | $62.23 | 2022-2025 | |
| Ironshore Pharmaceuticals INC. | $60.98 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.12 | 2021-2025 | Trintellix |
| Lundbeck LLC | $53.58 | 2022-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $24.05 | 2025 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $21.11 | 2025 | Auvelity |
| Allergan, INC. | $17.56 | 2021 | |
| Eisai INC. | $17.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Concey Ramold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.